Fevipiprant (BioDeep_00000179036)

   

human metabolite blood metabolite


代谢物信息卡片


2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid

化学式: C19H17F3N2O4S (426.08610780000004)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O
InChI: InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)

描述信息

D006133 - Growth Substances > D010937 - Plant Growth Regulators > D007210 - Indoleacetic Acids
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent
C177182 - Prostaglandin Receptor Antagonist

同义名列表

6 个代谢物同义名

2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; (1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methylpyrrolo[2,3-b]pyridin-3-yl)acetic acid; 1-(4-Methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; Fevipiprant; NVP-QAW039; QAW039



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • H Markus Weiss, Thomas Langenickel, Meredith Cain, Swarupa Kulkarni, Bharti Shah, Janardhana Vemula, Gholamreza Rahmanzadeh, Birk Poller. Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator. Drug metabolism and disposition: the biological fate of chemicals. 2021 05; 49(5):389-394. doi: 10.1124/dmd.120.000273. [PMID: 33632715]
  • H Markus Weiss, Ken-Ichi Umehara, Veit J Erpenbeck, Meredith Cain, Janardhana Vemula, Walid Elbast, Markus Zollinger. A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach. Drug metabolism and disposition: the biological fate of chemicals. 2020 10; 48(10):917-924. doi: 10.1124/dmd.120.090852. [PMID: 32739890]
  • Birk Poller, Ralph Woessner, Avantika Barve, Hanns-Christian Tillmann, Janardhana Vemula, Alexandra Nica, Walid Elbast, Hilmar Schiller, Peter End, Gian Camenisch, Markus Weiss. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Pulmonary pharmacology & therapeutics. 2019 08; 57(?):101809. doi: 10.1016/j.pupt.2019.101809. [PMID: 31195091]
  • Lei Wang, Dandan Yao, R N V Krishna Deepak, Heng Liu, Qingpin Xiao, Hao Fan, Weimin Gong, Zhiyi Wei, Cheng Zhang. Structures of the Human PGD2 Receptor CRTH2 Reveal Novel Mechanisms for Ligand Recognition. Molecular cell. 2018 10; 72(1):48-59.e4. doi: 10.1016/j.molcel.2018.08.009. [PMID: 30220562]
  • David Pearson, H Markus Weiss, Yi Jin, Jan Jaap van Lier, Veit J Erpenbeck, Ulrike Glaenzel, Peter End, Ralph Woessner, Fabian Eggimann, Gian Camenisch. Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro. Drug metabolism and disposition: the biological fate of chemicals. 2017 07; 45(7):817-825. doi: 10.1124/dmd.117.075358. [PMID: 28442499]
  • Veit J Erpenbeck, Eva Vets, Lien Gheyle, Wande Osuntokun, Michael Larbig, Srikanth Neelakantham, David Sandham, Gerald Dubois, Walid Elbast, Paul Goldsmith, Markus Weiss. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers. Clinical pharmacology in drug development. 2016 Jul; 5(4):306-13. doi: 10.1002/cpdd.244. [PMID: 27310331]